埃格列净(Inn；商标名称StigalTro)是一种治疗2型糖尿病的药物。在美国，它被食品和药物管理局批准作为单一疗法和固定剂量联合使用西他列汀或二甲双胍。在欧洲，它在2018年3月被批准用于单一疗法或联合疗法。
2-Chloro-5-methylbenzoic acid
(S)-5-Oxopyrrolidine-2-carboxylic acid
(3aS,4S,6R,6aS)-6-((R)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-ol
1-Methylpiperazine
(2S,3R,4S,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
N,O-Dimethylhydroxylamine hydrochloride
2,3,4,6-Tetra-O-benzyl-D-glucono-1,5-lactone
Ethoxybenzene
Iodomethyl pivalate
1,3-Propanedithiol
2,3,4,6-Tetra-O-(trimethylsilyl)-D-glucono-delta-lactone
4-Bromo-1-chloro-2-(4-ethoxybenzyl)benzene
(S)-5-Oxopyrrolidine-2-carboxylic acid compound with (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1)
(1R,2S,3S,4R,5S)-1-(Acetoxymethyl)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triyl triacetate
(2S,3R,4S,5S)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6,6-bis(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
(3AS,4S,6R,6aS)-6-((tert-butyldimethylsilyl)oxy)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carbaldehyde
2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1,3-dithiane
2-((Benzyloxy)(4-ethoxyphenyl)methyl)-4-bromo-1-chlorobenzene
